GSK/Theravance Press Forward With Once-Daily LABA After FDA Vote On Asthma Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms await Phase IIb results for new inhaled corticosteroid to develop Phase III testing plan for potential successor to Advair.
You may also be interested in...
New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products
Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol
FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.
Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD
Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.